20171012 PR TG4010 publications
Category: Press release
Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
20171002-PR-TG-Randox-final
Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
20170905 Invirio PR US
First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
170919-Transgene-FPI-Announcement_US
First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
20170913 EN – CP Resultats financiers final
Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)
Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
20170907-ESMO-Metromajx-poster-EN
Transgene Announces Upcoming Investor Meetings
TNG-PR-financial-agenda-H217-EN
First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
PR Pexa-Vec nivo EN
Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
20170724 PR CancerResearch